CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Convalescent Plasma TransfusionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug679 Random Donor Plasma Wiki 1.00
drug800 Supportive Care Wiki 1.00
drug533 NORS (Nitric Oxide Releasing Solution) Wiki 0.71

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.12
D014777 Virus Diseases NIH 0.11
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial

Currently, no effective treatments are available for the COVID-19 pandemic, which is related to more than 70,000 deaths all over the world. Scientists and Researchers are working on many aspects of treatment options for the development of vaccination and medication to combat this life-threatening problem. Convalescent plasma from recovered COVID-19 patients contains antibodies against COVID-19 which may be beneficial to severely sick COVID019 infected patients. We have planned a randomized controlled trial to assess the efficacy of this therapy in COVID-19 infected sick patients. We will collect up to 500 ml Convalescent Plasma from the COVID-19 infected recovered patient after 14 days of clinical and radiological recovery with two consecutive COVID-19 negative tests by PCR. We will further test the sample from the collected plasma for COVID-19 specific antibodies and their titer. This plasma will be frozen and sent to the treating center (MAMC). 200-600 ml of convalescent plasma will be transfused to patients who fit the eligibility criteria and are randomized to the convalescent plasma group. This will be done in severely sick patients. Data will be collected for the benefit and adverse events related to convalescent plasma transfusion.

NCT04346446 COVID Drug: Convalescent Plasma Transfusion Other: Supportive Care Drug: Random Donor Plasma

Primary Outcomes

Measure: Proportion of patients remaining free of mechanical ventilation in both groups

Time: Day 7

Secondary Outcomes

Measure: Mortality in both groups

Time: Day 28

Measure: Improvement in Pa02/Fi02 ratio in both groups

Time: Day 2

Measure: Improvement in Pa02/Fi02 ratio in both groups

Time: Day 7

Measure: Improvement in SOFA score in both groups

Time: Day 2

Measure: Improvement in SOFA score in both groups

Time: Day 7

Measure: Duration of hospital Stay in both group.

Time: Day 28

Measure: Duration of Intensive Care Unit stay in both groups.

Time: Day 28

Measure: Requirements of Vasopressor in both groups.

Time: Day 28

Measure: Days free of dialysis in both groups.

Time: Day 28


No related HPO nodes (Using clinical trials)